real-time news and commentary for investors
Wednesday, Jan 18
2012, 12:01 PM
Research from Frost & Sullivan breathes some life into the potential for generic drug makers...
Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil.